Bevacizumab: A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

Author： Croom Katherine F.   Dhillon Sohita  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.16, 2011-11, pp. : 2213-2229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-line therapy with trastuzumab plus paclitaxel and carboplatin may be active in patients with HER-2 over-expressing metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer

By Scott Lesley J.  

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1793-1799

Adis International

Access to resources Recommend Favorite

Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer

By Keating Gillian M.  

Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. : 353-360

Adis International

Access to resources Recommend Favorite

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer: A Viewpoint by David Miles

By Miles David  

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1800-1801

Adis International

Access to resources Recommend Favorite

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

By Ko Andrew  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1597-1606

Springer Publishing Company

Access to resources Recommend Favorite